Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Copenhagen, Feb. 24, 2016 -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 28(a) of the Danish Securities Trading Act, ALK-Abello A/S shall report transactions under securities identification code (ISIN) DK0060027142, ALK-Abello B shares under the symbol ALK B:
| Name | Jens Bager |
| Reason | Former President and CEO. Comprised by ALKs insider rules about reporting transactions during his resignation period of 6 months |
| Issuer | ALK-Abello A/S |
| ISIN code | DK0060027142 |
| Type | B-shares |
| Transaction | Purchase |
| Trading date | 24 February 2016 |
| Market | NASDAQ Copenhagen |
| Number | 5,000 |
| Market value | DKK 4,897,700 |
ALK-Abello A/S
For further information please contact:
Flemming Pedersen, CFO, tel: +45 4574 7576
